EX-TEM. FIB-TEM, AND AP-TEM FOR ROTEM DELTA THROMBOELASTOMETRY SYSTEM

{0} 1 # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: k101533 B. Purpose for Submission: Bundled submission for clearance of new assays C. Measurand: Coagulation Factors (extrinsic pathway) D. Type of Test: Clotting E. Applicant: TEM Innovations GmbH F. Proprietary and Established Names: EXTEM® Assay, FIBTEM® Assay, APTEM® Assay for the ROTEM® delta Thromboelastometry System ROTROL N ROTROL P G. Regulatory Information: 1. Regulation section: 21 CFR §864.5425 - Multipurpose system for in vitro coagulation studies 2. Classification: Class II 3. Product code: JPA – System, Multipurpose for in vitro coagulation studies 4. Panel: 81 Hematology H. Intended Use: 1. Intended use(s): The EXTEM® assay is a semi-quantitative in vitro diagnostic assay used to monitor the coagulation process via the extrinsic pathway in citrated whole blood specimens on the ROTEM® delta Thromboelastometry System. Clotting characteristics are described by the functional parameters Clotting Time (CT), Speed of Clot formation (CFT and alpha angle), Clot Firmness (A20/MCF) and Clot Lysis (LOT, ML, LI(x)). CFT and alpha (Speed of Clot Formation) are complementary parameters and should be used in conjunction with the main parameters Clotting Time (CT) and Clot Firmness (A20/MCF). The FIBTEM® assay is a semi-quantitative in vitro diagnostic assay on the ROTEM® delta Thromboelastometry System to monitor the clot firmness of a citrated whole blood specimen after blocking platelet contribution to the clot firmness. The fibTEM® is always used in conjunction with exTEM®. Clotting characteristics are described by the functional parameter Clot Firmness (A20/MCF). The APTEM® assay is a semi-quantitative in vitro diagnostic assay on the ROTEM® {1} delta Thromboelastometry System to monitor the clot firmness of a citrated whole blood specimen after blocking hyperfibrinolysis by aprotinin. The ap-TEM® is always used in conjunction with ex-TEM®. Clotting characteristics are described by the functional parameters Clotting Time (CT), Speed of Clot formation (CFT and alpha angle), Clot Firmness (A20/MCF) and Clot Lysis (LOT, ML, LI(x)). CFT and alpha (Speed of Clot Formation) are complementary parameters and should be used in conjunction with the main parameters Clotting Time (CT) and Clot Firmness (A20/MCF). 2. Indication(s) for use: Each assay, APTEM, EXTEM and FIBTEM is performed on the ROTEM delta analyzer which has the following indication for use: The indication for ROTEM® delta is in adult patients when an evaluation of their blood coagulation properties is desired. Coagulation evaluations with the ROTEM® delta system are commonly used to assess clinical conditions in organ transplantation, cardiovascular surgery, cardiology procedures and trauma to access post-operative hemorrhage and/or thrombosis. 3. Special conditions for use statement(s): Prescription Use Only 4. Special instrument requirements: ROTEM® delta instrument I. Device Description: The ROTEM® delta EXTEM® reagent consists of a rabbit brain thromboplastin, heparin inhibitor, phospholipids, preservatives, and buffer. It is available as a 10 vial kit. The ROTEM® delta FIBTEM® is a mixture of a platelet inhibitor (cytochalasin D) and $\mathrm{CaCl}_2$ , buffer and preservative. It is available as a 10 vial kit. The ROTEM® delta APTEM® contains aprotinin, $\mathrm{CaCl}_2$ , buffer and preservative. ROTROL N and ROTROL P consist of lyophilized plasma, fibrinogen, and buffer. J. Substantial Equivalence Information: 1. Predicate device name(s): Haemoscope Corporation Thrombelastograph® Coagulation Analyzer (TEG®) 5000 Series 2. Predicate 510(k) number(s): k895844, k904204, k954437, k993678, k002177 3. Comparison with predicate: EXTEM® | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Intended Use | The EXTEM is a semi-quantitative in vitro diagnostic assay used to monitor the coagulation process via the extrinsic pathway in citrated whole blood specimens on the ROTEM delta®. Clotting characteristics are described by the functional | The TEG - 5000 Series Analyzer is intended to be used to provide a quantitative and qualitative indication of the coagulation state of a blood sample by monitoring, measuring, analyzing and reporting coagulation parameter information. The | {2} | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | | parameters Clotting Time (CT), Speed of Clot Formation (CFT and alpha angle), Clot firmness and Clot Lysis (LOT, ML, LI(x)). | Thrombelastograph (TEG) Coagulation Analyzer TEG - 5000 Series records the kinetic changes in a sample of whole blood, plasma or platelet rich-plasma as the sample clots (R or R-Time, K or K-TIME, Angle, and MA), retracts and/or lyses (breaks apart) (LY30/LY60, A30/A60, EPL, CLT, and LTE). | | Activation Principle | Tissue Factor (TF) | Same | | Extrinsic contact Activation Reagent | Rabbit brain thromboplastin, CaCl2 | Same | | Differences | | | | --- | --- | --- | | Item | Device | Predicate | | Sample size | 300 μL citrated whole blood | 360 μL citrated whole blood | | Instrument | ROTEM delta instrument | TEG-5000 series analyzers | FIBTEM® | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Intended Use | The FIBTEM assay is a semiquantitative in vitro diagnostic assay on the ROTEM® delta Thromboelastrometry System to monitor the clot firmness of a citrated whole blood specimen after blocking platelet contribution to the clot firmness. Fib-TEM® is always used in conjunction with ex-TEM®. Clotting characteristics are described by the functional parameter Clot Firmness (A20/MCF). | The TEG - 5000 Series Analyzer is intended to be used to provide a quantitative and qualitative indication of the coagulation state of a blood sample by monitoring, measuring, analyzing and reporting coagulation parameter information. The Thrombelastograph (TEG) Coagulation Analyzer TEG - 5000 Series records the kinetic changes in a sample of whole blood, plasma or platelet rich-plasma as the sample clots (R or R-Time, K or K-TIME, Angle, and MA), retracts and/or lyses (breaks apart) (LY30/LY60, A30/A60, EPL, CLT, and LTE). | | Activation Principle | Tissue Factor | Same | | Reagent | Rabbit brain thromboplastin, CaCl2. | Same | | Differences | | | | --- | --- | --- | | Item | Device | Predicate | | Platelet Blocker | Cytochalasin D | ReoPro® | | Instrument | ROTEM delta instrument | TEG 5000 series analyzer | {3} APTEM® | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Intended Use | The APTEM assay is a semiquantitative in vitro diagnostic assay on the ROTEM® delta Thromboelastrometry System to monitor the clot firmness of a citrated whole blood specimen after blocking hyperfibrinolysis by aprotinin. ap-TEM® is always used in conjunction with ex-TEM®. Clotting characteristics are described by the functional parameter Clot Firmness (A20/MCF) | The TEG - 5000 Series Analyzer is intended to be used to provide a quantitative and qualitative indication of the coagulation state of a blood sample by monitoring, measuring, analyzing and reporting coagulation parameter information. The Thrombelastograph (TEG) Coagulation Analyzer TEG - 5000 Series records the kinetic changes in a sample of whole blood, plasma or platelet rich-plasma as the sample clots (R or R-Time, K or K-TIME, Angle, and MA), retracts and/or lyses (breaks apart) (LY30/LY60, A30/A60, EPL, CLT, and LTE). | | Activation Principle | Tissue Factor | Same | | Reagent | Rabbit brain thromboplastin, CaCl_{2}, | Same | | Fibrinolytic Blocker | Aprotinin | Same | | Differences | | | | --- | --- | --- | | Item | Device | Predicate | | Sample size | 300 μL citrated whole blood | 360 μL citrated whole blood | | Instrument | ROTEM delta instrument | TEG 5000 series analyzer | ## K. Standard/Guidance Document Referenced (if applicable): EN ISO 13485:2003 Medical devices – Quality management systems – Requirements for regulatory purposes (ISO 13485:2003) German Version EN ISO 13485:2003 EN ISO 14971:2001 + A1 Medical devices – Application of risk management to medical devices (ISO 14971:2000 + A1:2003) German Version EN ISO 14971:2001 + A1:2003 CLSI EP09-A2, Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline. (In Vitro Diagnostics) Date of Standard: 2002 CLSI EP05-A, Vol.19, No. 2 Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline Date of Standard: 1999 CLSI C28-A2, How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline – Second Edition. (In Vitro Diagnostics) Date of Standard: 2000 CLSI EP07-A, Vol. 22, No. 27 Interference Testing in Clinical Chemistry; Approved Guideline Guidance for Industry and FDA Staff: 510(k) Submissions for Coagulation Instruments (June 19, 2003) {4} Guidance for Industry and FDA Staff: Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005) L. Test Principle: Thromboelastometry is based on the measurement of elasticity of blood by continuous graphic logging of the firmness of a blood clot during clot formation (coagulation factors and inhibitors, platelets and fibrin) and subsequent fibrinolysis. The EXTEM assay is similar to the laboratory prothrombin time (PT) test. Calcium chloride (CaCl₂) and EXTEM® reagent are pipetted into the assay cup and then citrated whole blood is added and mixed. The cup is then inserted into the measurement position of the ROTEM® delta analyzer and the reaction is recorded. The initiation phase (clotting time = CT) is the time from test start until the formation of first significant detectable fibrin is reached. The clot formation phase (CFT) is the time from the CT until a clot firmness of 20 mm is reached. The A10 and A20, is the clot firmness at 10 and 20 minutes after CT. Maximum clot firmness (MCF) measures the maximum amplitude of the developed clot, and the alpha angle is the angle between the baseline and a tangent to the clotting curve through the 2 mm point. The FIBTEM assay measures the fibrin contribution to clot firmness. Equal amounts of EXTEM® and FIBTEM® reagents are pipetted into the instrument sample cup, and then patient sample is added and mixed with the reagents. The cup is then inserted into the measurement position of the ROTEM® delta analyzer and the reaction recorded. The initiation phase (clotting time = CT) gives information on the extrinsic clotting factor concentration. The A20, MCF parameters give information on the overall colt firmness without platelet activity. The APTEM assay provides information (clotting time, speed of clot formation, and clot firmness) without fibrinolysis effects. Evidence of fibrinolytic activity is obtained by comparing the results of the EXTEM and APTEM test. In the APTEM assay, activation is initiated by the EXTEM® reagent via the extrinsic system in conjunction with the plasmin-antagonist Aprotinin, which prevents fibrinolysis. Fibrinolytic processes are detected by a loss of the clot firmness during the clot formation analysis with the ROTEM® delta in the EXTEM assay. M. Performance Characteristics (if/when applicable): 1. Analytical performance: a. Precision/Reproducibility: Total, within-run (channel-to-channel) and operator-to-operator precision were evaluated. The sample pool consisted of the following sample types: - Normal blood samples in the manufacturer established reference ranges - Level 1 blood samples at the medical decision limit between normal and hypocoagulable: normal blood samples diluted with physiologic saline solution and spiked with a direct thrombin inhibitor - Level 2 blood samples outside the reference ranges (at the medical decision limit between normal and hypercoagulable): normal sample spiked with fibrinogen (up to approximately 8 g/L) - ROTROL N (level 1 - mimicking 'normal') 5 {5} - ROTROL P (level 2 - mimicking ‘pathological’) Citrated whole blood samples were obtained from a blood donor center, and from these normal blood samples, the level 1 and level 2 blood samples were generated by diluting or spiking. Within-run precision was assessed by performing five consecutive runs of each sample/control. Each run was performed using four different channels of one ROTEM® instrument in parallel which resulted in 20 replicates per test and sample. Because the FIBTEM assay contains a platelet inhibitor, only the fibrin contribution to clot firmness is measured in the assay. Therefore, only the clot firmness parameter A20 is relevant for precision testing. Rotrol N and Control P results were deemed acceptable if the results fell within the acceptable range for the control. Results from the Normal Donor and Level 1 &amp; 2 Samples were deemed acceptable based on the following: EXTEM/ FIBTEM/APTEM Acceptance Criteria | | CT CV (%) | CFT CV (%) | A-angle CV (%) | A20 CV (%) | | --- | --- | --- | --- | --- | | Within-run | <10 | <20 | <5 | <5 | | Between Operator | <10 | <30 | <5 | <6 | Results are summarized below: Primary Parameters A20 within-run precision (n=20) | | Normal Donor CV% | Level 1 CV% | Level 2 CV% | ROTROL N CV% | CONTROL P CV% | | --- | --- | --- | --- | --- | --- | | EXTEM | 1.9 | 6.0 | 2.7 | 11 | 5.0 | | APTEM | 2.7 | 3.3 | 2.5 | N/A | N/A | | FIBTEM | 2.9 | 11.5 | 2.9 | N/A | N/A | CT within-run precision (n=20) | | Normal Donor CV% | Level 1 CV% | Level 2 CV% | ROTROL N CV% | CONTROL P CV% | | --- | --- | --- | --- | --- | --- | | EXTEM | 4.4 | 6.7 | 5.6 | 3.1 | 4.2 | | APTEM | 7.8 | 7.1 | 6.2 | N/A | N/A | | FIBTEM* | N/A | N/A | N/A | N/A | N/A | *Only the Amplitude parameters (A10, A20, and MCF) are relevant for the FIBTEM assay. {6} # Secondary Parameters CFT within-run precision (n=20) | | Normal Donor CV% | Level 1 CV% | Level 2 CV% | ROTROL N CV% | CONTROL P CV% | | --- | --- | --- | --- | --- | --- | | EXTEM | 5.5 | 19.1 | 34.6* | 21.0* | 34.5* | | APTEM | 7.3 | 9.5 | 15.4 | N/A | N/A | | FIBTEM* | N/A | N/A | N/A | N/A | N/A | *Not clinically significant. CFT is an ancillary parameter, no clinical decision based solely on CFT. Alpha Angle within-run precision (n=20) | | Normal Donor CV% | Level 1 CV% | Level 2 CV% | ROTROL N CV% | CONTROL P CV% | | --- | --- | --- | --- | --- | --- | | EXTEM | 1.4 | 5.3 | 1.2 | 0.6 | 1.7 | | APTEM | 2.2 | 3.1 | 0.7 | N/A | N/A | | FIBTEM* | N/A | N/A | N/A | N/A | N/A | # Total Precision EXTEM, the activator for all three assays (EXTEM, APTEM, FIBTEM) was investigated for total precision (between-run) by analyzing ROTROL N and ROTROL P in duplicate on two separate runs, over 20 working days. The two test runs were separated by at least two hours. Results were presented using arithmetic means and the $S_{\mathrm{wr}}$ and $S_{\mathrm{T}}$ standard deviations. Additionally, between-day ( $S_{\mathrm{dd}}$ ) and between-run ( $S_{\mathrm{rr}}$ ) standard deviations were presented. A20 | | ROTROL N | | | | | | ROTROL P | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | n | Mean | Sdd | Srr | Swr | ST | n | Mean | Sdd | Srr | Swr | ST | | EXTEM | 80 | 42.2 | 1.3 | 1.3 | 0.7 | 2.0 | 80 | 24.6 | 0.4 | 0.0 | 0.8 | 0.9 | CT | | ROTROL N | | | | | | ROTROL P | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | n | Mean | Sdd | Srr | Swr | ST | n | Mean | Sdd | Srr | Swr | ST | | EXTEM | 80 | 45.2 | 1.0 | 1.2 | 1.9 | 2.4 | 80 | 91.4 | 3.2 | 2.8 | 4.8 | 6.4 | CFT | | ROTROL N | | | | | | ROTROL P | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | n | Mean | Sdd | Srr | Swr | ST | n | Mean | Sdd | Srr | Swr | ST | | EXTEM | 80 | 24.4 | 0.6 | 2.9 | 2.2 | 3.7 | 80 | 274.8 | 34.1 | 0.0 | 67.7 | 75.8 | {7} Alpha Angle | | ROTROL N | | | | | | ROTROL P | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | n | Mean | Sdd | Srr | Swr | ST | n | Mean | Sdd | Srr | Swr | ST | | EXTEM | 80 | 85.9 | 0.1 | 0.0 | 0.4 | 0.4 | 80 | 75.8 | 0.6 | 0.8 | 1.1 | 1.4 | Between-Operator Precision Between-operator precision was investigated by five different operators analyzing the two control samples on one working day, using two different channels per test and sample. | | ROTROL N CV% | | | | ROTROL P CV% | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | A20 | CT | CFT | Alpha | A20 | CT | CFT | Alpha | | EXTEM | 5.5 | 7.9 | 13.4 | 0.3 | 2.4 | 5.6 | 22.4 | 2.1 | Within-Run Reproducibility A within-run reproducibility study was conducted using 3 sites, 3 lots and 3 different instruments. ROTROL N and ROTROL P were run eight times for each lot (n=24/lot). | | ROTROL N %CV | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Lot 1 | | | | Lot 2 | | | | Lot 3 | | | | | | CT | CFT | A20 | Alpha angle | CT | CFT | A20 | Alpha angle | CT | CFT | A20 | Alpha angle | | EXTEM | 3.6 | 9.4 | 2.0 | 0.2 | 8.6 | 11.8 | 2.7 | 0.5 | 3.8 | 8.7 | 3.2 | 0.6 | | | ROTROL P %CV | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Lot 1 | | | | Lot 2 | | | | Lot3 | | | | | | CT | CFT | A20 | Alpha angle | CT | CFT | A20 | Alpha angle | CT | CFT | A20 | Alpha angle | | EXTEM | 7.2 | 19.7 | 3.5 | 2.5 | 7.0 | 17.1 | 3.2 | 1.9 | 12.4 | 15.2 | 2.7 | 4.2 | b. Factor sensitivity to Factor VII (FVII) for the EXTEM assay was demonstrated by diluting calibration plasma (IL Calibration Plasma k041905, Factor VII level = 105%) with Factor VII deficient plasma (IL Factor VII Deficient Plasma, k024082 Factor VII level = 1%) and testing. Four aliquots of each data point were prepared, run, and the mean of the four determinations plotted against FVII concentration. Because the CT-parameter is the most sensitive signal for factor deficiency, only CT-values of the ex-TEM® reagent were estimated. Results demonstrated that Factor VII levels &lt;20% significantly prolong the CT. {8} 9  Effect of FVII Level on CT EXTEM c. Linearity/assay reportable range: Not applicable d. Traceability, Stability, Expected values (controls, calibrators, or methods): Data was submitted to support the 8-hour on-board and 14-day open vial stability claims for the ex-TEM, fib-TEM, and ap-TEM reagents. To support the 8-hr on board stability claim, all reagents were opened and stored at 25°C and tested at 1-hr intervals. ROTROL N was used as the sample material. Results were deemed acceptable if the ratio from the mean of the first three data points (hrs. 1-3) and the mean of the last three data points (hrs 6-8) is less than 15% for the CT parameter, CFT &lt;25%, A20 &lt;5% (fib-TEM &lt;20%), and &lt;5% for the Alpha parameter. For the 14-day stability study, reagent vials were opened, used, closed, stored at 2-8°C, and tested on days 3, 7, 10, and 14. ROTROL N was used as the sample material. All reagents have shown stability up to 14 days without any significant changes. e. Detection limit: Not applicable f. Analytical specificity: Aprotinin, tranexamic acid and epsilon-aminocaproic acid (EACA) interference were evaluated per CLSI EP7A. The three potential interferents were spiked in vitro with two concentrations (one at the highest concentration reported or three times the maximum therapeutic dose, and a lower -but still high concentration) of the antifibrinolytic substances and compared to the non-spiked interferent free control sample. {9} | Interferent | Maximum Concentration | Lower Concentration | | --- | --- | --- | | Aprotinin | 400 KIU/mL | 200 KIU/mL | | Tranexamic Acid | 60 μg/mL | 30 μg/mL | | EACA | 600 μg/mL | 300 μg/mL | Results showed that none of the possible interferents had an influence on the extrinsic coagulation activation up to at least twice the highest clinical dose. Interference data for unfractionated heparin, for dilution effect, and for urokinase on the EXTEM, APTEM, and FIBTEM assays, were provided to demonstrate thromboelastograph principles: coagulation kinetics, clot firmness, and hyperfibrinolysis. Testing was conducted by testing five dilution levels of the interferent in normal blood (n=10) in parallel with the undiluted blood sample. Heparin was spiked into citrated blood samples from blood donors in the concentrations 2, 3, 4, 5, and 8 U/mL to determine the maximum concentration which leaves the CT and MCT/A20 unaltered. Four aliquots of each heparin concentration level was prepared and assayed. The mean and SD for each concentration was presented. For the 5 and 8 U/mL aliquots, the median CT results were prolonged in comparison to the heparin free control, and were above the upper reference range limit. A similar less pronounced effect was seen on the CFT, Alpha Angle, and A20 parameters. Sensitivity to dilution effect was presented to demonstrate clot firmness. Blood samples depleted of platelets or fibrinogen decreases clot firmness. To simulate the depletion of platelets and fibrinogen due to plasma expander substitution in a patient, normal blood was diluted in saline to 90, 80, 70, 60 and 50%. Ten different blood samples from normal donors were diluted and tested in parallel. The mean, SD, median, upper and lower quartile, min, and max over the ten samples was determined for each dilution. The median and upper and lower quartile was presented graphically (median ± quartile) by dilution. A linear reduction was seen with each dilution on all EXTEM, APTEM, and FIBTEM parameters. Urokinase (UK), a plasmin activator was used to show a relationship between activation of plasmin and concomitant hyperfibrinolysis and the breakdown of the clot in EXTEM. UK was spiked into normal citrated blood samples in the concentrations 10, 20, 30, 40, and 50 U/mL and the EXTEM and APTEM assays were performed. Ten different blood samples from normal donors were diluted and tested in parallel. The mean, SD, median, upper and lower quartile, min, and max over the ten samples was determined for each dilution. The median and upper and lower quartile was presented graphically (median ± quartile) by dilution. Clot lysis was seen within one hour in the 20, 30, 40 and 50 U/mL concentrations for the EXTEM assays. UK did not affect any parameter of the APTEM assay, indicating that the aprotinin in APTEM assay blocks fibrinolysis. g. Assay cut-off: Not applicable 2. Comparison studies: {10} a. Method comparison with predicate device: Clinical samples from patients $(n = 78)$ with suspected or acute hemostasis disorders in the peri- or post-operative phase or at the ICU from 3 US sites were enrolled into the study. The study included patients with normal coagulation, hypocoagulable and hypercoagulable states in order to obtain results over the whole range of the individual parameter results. A unique sample identifier, the reason for the surgery, and a brief qualitative description of the clinical finding at the time of blood draw were obtained for each patient included in the study. The samples for the activated tests were analyzed within two hours from blood draw, the non-activated test (NATEM) was analyzed within one hour. The EXTEM assay run on the ROTEM® delta was compared to a generic tissue factor reagent run on the predicate device. The FIBTEM assay run on the ROTEM® delta was compared to tissue factor reagent plus ReoPro® run on the predicate. The APTEM assay run on the ROTEM® delta was compared to the tissue factor reagent with aprotinin run on the predicate. Due to limited blood volumes taken, not all patients were tested with all assays per protocol. At one site, 6 patients were tested at multiple time points during surgery. Data from each site was analyzed by Ordinary Least Squares and Deming regression and results demonstrated no significant difference between sites. EXTEM MCF vs. TEG MA | | N | Min ROTEM®/ TEG® | Max ROTEM®/ TEG® | Slope Deming | Intercept Deming | R | | --- | --- | --- | --- | --- | --- | --- | | All Sites | 70 | 36/33 | 80/78 | 0.97 | 0.15 | 0.9979 | | Atlanta | 27 | 38/42 | 75/73 | 1.09 | -6.55 | 1.0072 | | Durham | 23 | 44/44 | 71/75 | 0.81 | 10.00 | 0.9852 | | Orlando | 20 | 36/33 | 80/78 | 0.98 | -1.25 | 0.9995 | CT vs. TEG R | | N | Min ROTEM®/ TEG® | Max ROTEM® /TEG® | Slope Deming | Intercept Deming | R | | --- | --- | --- | --- | --- | --- | --- | | All Sites | 71 | 1/0 | 5/4 | 1.21 | 0.10 | 1.0314 | | Atlanta | 28 | 1/1 | 2/2 | 2.24 | -1.00 | 1.3019 | | Durham | 23 | 1/0 | 2/1 | 1.07 | 0.35 | 1.0209 | | Orlando | 20 | 1/1 | 5/4 | 1.11 | 0.09 | 1.0033 | {11} 12 APTEM MCF vs. TEG MA | | n | Min ROTEM®/ TEG® | Max ROTEM®/ TEG® | Slope Deming | Intercept Deming | R | | --- | --- | --- | --- | --- | --- | --- | | All Sites | 55 | 35/38 | 80/77 | 0.98 | -0.41 | 0.9975 | | Atlanta | 14 | 35/40 | 64/69 | 0.99 | -1.15 | 0.9990 | | Durham | 21 | 45/38 | 67/74 | 0.68 | 17.76 | 0.9425 | | Orlando | 20 | 38/40 | 80/77 | 1.16 | -11.98 | 1.0070 | CT vs. TEG R | | n | Min ROTEM®/ TEG® | Max ROTEM®/ TEG® | Slope Deming | Intercept Deming | R | | --- | --- | --- | --- | --- | --- | --- | | All Sites | 55 | 1/0 | 5/4 | 1.52 | -0.08 | 1.0484 | | Atlanta | 14 | 1/1 | 4/2 | 2.82 | -1.54 | 1.3533 | | Durham | 21 | 1/0 | 2/2 | 1.11 | 0.32 | 1.0273 | | Orlando | 20 | 1/1 | 5/4 | 1.42 | -0.99 | 1.0074 | FIBTEM MCF vs. TEG MA | | n | Min ROTEM®/ TEG® | Max ROTEM®/ TEG® | Slope Deming | Intercept Deming | R | | --- | --- | --- | --- | --- | --- | --- | | All Sites | 65 | 2/3 | 45/47 | 1.11 | -5.78 | 1.0090 | | Atlanta | 23 | 2/3 | 44/43 | 1.04 | -4.58 | 1.0024 | | Durham | 22 | 8/13 | 45/35 | 1.48 | -14.01 | 1.0459 | | Orlando | 20 | 6/5 | 44/47 | 0.99 | -2.87 | 0.9996 | b. Matrix comparison: Not applicable 3. Clinical studies: a. Clinical Sensitivity: Not applicable b. Clinical specificity: Not applicable c. Other clinical supportive data (when a. and b. are not applicable): Not applicable 4. Clinical cut-off: Not applicable 5. Expected values/Reference range: Reference ranges for the ROTEM® were determined following the CLSI C28-A2 {12} guideline at 3 US sites (n=127 apparently healthy blood donors). The reference ranges showed no significant difference between centers or from ranges established at European sites. Each laboratory is recommended to establish a site specific reference range. | | | MCF (MM) | A20(mm) | CT(sec) | CFT(sec) | Alpha(°) ROTEM® | | --- | --- | --- | --- | --- | --- | --- | | EXTEM | US | 52-70 | 50-70 | 43-82 | 48-127 | 65-80 | | FIBTEM | US | 7-24 | 7-24 | | | | | APTEM | US | 52-70 | 50-70 | 43-82 | 48-127 | 65-80 | ## N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10. ## O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. 13